Summary
Bromocriptine (CB-154) is regarded as a dopamine agonist, hence is used in the treatment of Parkinson's disease. In the paper presented a possibility of the influence of bromocriptine on central serotonin neurons has been studied.
It was demonstrated that CB-154, like tryptophan, 5-hydroxy-tryptophan, LSD or fenfluramine in previous experiments, potentiates the flexor reflex of the spinal rat, and this effect of CB-154 is prevented by serotonin antagonists-cyproheptadine and danitracen.
CB-154, like fenfluramine used as a comparative serotonergic agent, rises the body temperature in rabbits. The hyperthermic effect of CB-154 is prevented by cyproheptadine, danitracen and mianserin. Haloperidol preventes the hyperthermia caused by a lower dose of CB-154 only, having no influence on the hyperthermic effects of greater doses of CB-154 or on fenfluramine-induced hyperthermia. The results obtained indicate that CB-154, besides a dopaminomimetic action, possesses central serotonin actions as well.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antkiewicz-Michaluk, L. The central action of ergometrine. The doctor thesis. Polish Academy of Sciences Institute of Pharmacology, Kraków 1976.
Burg, W. J. van der, Bonta, J. L., Delobelle, J., Ramon, C., Vargaftig, B. A novel type of substituted piperazine with high antiserotonin potency. J. Med. Chem.13, 35–39 (1970).
Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P. Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol.25, 409–411 (1973).
Costa, E., Groppetti, A., Revuelta, A. Action of fenfluramine on monoamine stores of rat tissue. Br. J. Pharmacol.41, 57–64 (1971).
Dray, A., Oakley, N. R. Bromocriptine and dopamine receptor stimulation. J. Pharm. Pharmacol.28, 586–588 (1976).
Engelhardt, G. Zur Pharmakologie des 9, 10-Dihydro-10-(1-methyl-4-piperidyliden)-9-anthrol (WA-335), eines Histamin- und Serotoninantagonisten. Arzneim.-Forsch. (Drug Res.)25, 1723–1737 (1975).
Frey, M. H., Magnussen, M. P. Different central medication of the stimulant effects of amphetamine and its p-chloroanalogue. Biochem. Pharmacol.17, 1229–1307 (1968).
Fuxe, K., Corrodi, H., Hökfelt, T., Lidbrink, P., Ungerstedt, U. Ergoconine and 2-Br-α-ergocriptine. Evidence for prolonged dopamine receptor stimulation. Med. Biol.52, 121–132 (1974).
Hill, H. F., Horita, A. Inhibition of (+)-amphetamine hyperthermia by blockade of dopamine receptors in rabbits. J. Pharm. Pharmacol.23, 715–717 (1971).
Hill, H. F., Horita, A. A pimozide sensitive effect of apomorphine on body temperature of the rabbit. J. Pharm. Pharmacol.24, 490–491 (1972).
Horita, A., Gogerty, J. H. The pyretogenic effect of 5-hydroxytryptophan and its comparison with that of LSD. J. Pharmacol. Exp. Ther.122, 195–200 (1958).
Horita, A., Hamilton, A. E. The effects of d, 1-α-methyltyrosine and L-DOPA on the hyperthermic and behavioral actions of LSD in rabbits. Neuropharmacol.12, 471–476 (1973).
Johnson, A. M., Loew, D. M., Vigouret, J. M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br. J. Pharmacol.56, 59 to 68 (1976).
Johnson, A. M., Vigouret, J. M., Loew, D. M.: CB-154 (2-Bromo-α-ergocryptine, Bromocriptine), a potential anti-Parkinsonian agent. N.-S. Arch. Pharmacol.282, suppl. 40 R (1974).
Kähling, J., Ziegler, H., Balhause, H. Zentrale Wirkungen von WA-335-BS, einer Substanz mit peripherer Antiserotonin- und Antihistamin-Wirkung. Arzneim.-Forsch. (Drug Res.)25, 1737–1744 (1975).
Maj, J., Baran, L., Rawłów, A., Sowińska, H. Central effects of mianserin and danitracen—new antidepressant of unknown mechanism of action. Pol. J. Pharmacol. Pharm.29, 213–214 (1977).
Maj, J., Baran, L., Sowińska, H., Gancarczyk, L. Central action of WA-335. Arch. Immunol. Ther. Exp.24, 205–222 (1976).
Maj, J., Kapturkiewicz, Z., Michaluk, J. The central action of nomifensine. Pol. J. Pharmacol. Pharm.28, 557–562 (1976).
Maj, J., Palider, W., Baran, L. The effect of serotoninergic and antiserotoninergic drugs on the flexor-reflex of spinal rat: a proposed model to evaluate the action on the central serotonin receptor. J. Neural Transm.38, 131–147 (1976).
Maj, J., Palider, W., Rawłów, A. The influence of mescaline on the flexor-reflex of the hind limb of the spinal rat. J. Pharm. Pharmacol.29, 177–178 (1977).
Palider, W., Rawłów, A.: Effect of serotonin uptake blocking agents on the flexor-reflex of the hind limb of the spinal rat. Pol. J. Pharmacol. Pharm.29 (1977, in press).
Persson, T., Waldeck, B. Is there an interaction between dopamine and noradrenaline containing neurons in the brain? Acta Physiol. Scand.78, 142–144 (1970).
Przewłocki, R. The influence of the central dopaminergic neurons stimulation on the activity of serotonin neurons. The doctor thesis. Polish Academy of Sciences, Institute of Pharmacology, Kraków 1975.
Quock, R. M., Beal, G. A. Fenfluramine-induced hyperthermia and stimulation in the rabbit. Res. Com. Chem. Path. Pharmacol.13, 401–409 (1976).
Quock, R. M., Beal, G. A., Chan, E. L. F. Quipazine: a serotoninergic hyperthermic agent in the rabbit. J. Pharm. Pharmacol.28, 170–172 (1976).
Quock, R. M., Horita, A. The interaction of naloxone with apomorphine induced hyperthermia in rabbits. Proc. West. Pharmacol. Soc.16, 68–69 (1973).
Quock, R. M., Horita, A. Apomorphine: modification of its hyperthermic effect in rabbits by p-chlorophenylalanine. Science183, 539–540 (1974).
Riezen, H. van Different central effects of 5-HT antagonists mianserin and cyproheptadine. Arch. Int. Pharmacodyn. Ther.198, 256–269 (1972).
Saxena, P. R., Houwellingen, P. van, Bonta, I. L. The effects of mianserin hydrochloride on the vascular responses evoked by 5-hydroxytryptamine and related vasoactive substances. Eur. J. Pharmacol.13, 295–305 (1971).
Schorderet, M. Direct evidence for the stimulation of rabbit retina dopamine receptors by ergot alkaloids. Neurosci. Lett.2, 87–91 (1976).
Snider, S. R., Hutt, Ch., Stein, B., Fahn, S. Increase in brain serotonin produced by bromocriptine. Neurosci. Lett.1, 237–241 (1975).
Snider, S. R., Hutt, Ch., Stein, B., Prasad, A. L. N., Fahn, S. Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. J. Pharm. Pharmacol.28, 563–566 (1976).
Southgate, P. J., Mayer, S. R., Boxall, E., Wilson, A. B. Some 5-hydroxy-tryptamine-like actions of fenfluramine: a comparison with (+)-amphetamine and diethylpropion. J. Pharm. Pharmac.23, 600–605 (1971).
Stone, S. A., Wenger, H. C., Luden, C. I., Stavorski, J. M., Ross, C. A. Antiserotonin, antihistaminic properties of cyproheptadine. J. Pharmacol. Exp. Ther.131, 73–84 (1961).
Vargaftig, B. B., Coignet, J. L., De Vos, C. J., Grijsen, H., Bonta, J. L. Mianserin hydrochloride: peripheral and central effects in relation to antagonism against-5-hydroxytryptamine and tryptamine. Eur. J. Pharmacol.16, 336–346 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maj, J., Gancarczyk, L. & Rawlów, A. The influence of bromocriptine on serotonin neurons. J. Neural Transmission 41, 253–264 (1977). https://doi.org/10.1007/BF01252020
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01252020